-
中文名称:人Ⅲ型前胶原(HPCⅢ)酶联免疫试剂盒
-
货号:CSB-E11989h
-
规格:96T/48T
-
价格:¥3600/¥2500
-
其他:
产品详情
-
产品描述:CUSABIO人Ⅲ型前胶原(HPCⅢ)酶联免疫检测试剂盒(货号:CSB-E11989h),采用双抗体夹心法定量检测血清样本中25 ng/mL至300 ng/mL浓度范围的HPCⅢ含量。HPCⅢ是细胞外基质中Ⅲ型胶原蛋白的前体物质,主要由活化的肝星状细胞分泌,其血清水平升高与肝纤维化进程密切相关,可作为评估肝脏纤维化程度的重要分子标志物。该试剂盒适用于体外研究领域,如通过检测动物模型或细胞培养上清中的HPCⅢ水平,探索肝纤维化发生机制、筛选抗纤维化药物活性,或用于基础医学研究中组织修复与纤维化相关疾病的病理分析。实验采用预包被特异性抗体的96孔板结构,通过标准品梯度稀释建立定量曲线,支持科研人员对血清样本进行快速、稳定的目标蛋白含量测定,为肝病研究、药物开发及分子生物学实验提供可靠的数据支持,本产品仅限于科学研究使用。
-
别名:procollagen type 3 ,HPC3|procollagen type III ,HPCⅢ procollagen type III ,HPCIII
-
缩写:HPCⅢ
-
种属:Homo sapiens (Human)
-
样本类型:serum
-
检测范围:25 ng/mL-300 ng/mL
-
灵敏度:25 ng/mL
-
反应时间:1-5h
-
样本体积:50-100ul
-
检测波长:450 nm
-
研究领域:Signal Transduction
-
测定原理:quantitative
-
测定方法:Sandwich
-
精密度:
Intra-assay Precision (Precision within an assay): CV%<15% Three samples of known concentration were tested twenty times on one plate to assess. Inter-assay Precision (Precision between assays): CV%<20% Three samples of known concentration were tested in twenty assays to assess. -
线性度:
To assess the linearity of the assay, samples were spiked with high concentrations of human HPCⅢ in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay. Sample Serum(n=4) 1:1 Average % 84 Range % 80-92 1:2 Average % 97 Range % 91-105 1:4 Average % 93 Range % 90-96 1:8 Average % 95 Range % 89-99 -
回收率:
The recovery of human HPCⅢ spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section. Sample Type Average % Recovery Range Serum (n=5) 96 89-101 EDTA plasma (n=4) 97 92-102 -
标准曲线:
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed. ng/ml OD1 OD2 Average 300 1.356 1.342 1.349 200 0.967 1.023 0.995 100 0.466 0.482 0.474 50 0.211 0.199 0.205 25 0.050 0.048 0.049 -
数据处理:
-
货期:3-5 working days
引用文献
- Clinical significance of decoy receptor 3 upregulation in patients with hepatitis B and liver fibrosis Xiaoli Lou.et al,Oncology Letters,2018